Journal article
Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab
Abstract
PurposeWe have limited capability to predict survival among patients treated for metastatic HER2-positive breast cancer. Further research is warranted to identify significant prognostic and predictive factors.MethodsWe identified all HER2-positive metastatic breast cancer patients receiving trastuzumab at the Sunnybrook Odette Cancer Centre (SOCC) from 1999 to 2013 through the Cancer Care Ontario (CCO) Registry (n = 256) and selected patients …
Authors
Blanchette PS; Desautels DN; Pond GR; Bartlett JMS; Nofech-Mozes S; Yaffe MJ; Pritchard KI
Journal
Breast Cancer Research and Treatment, Vol. 170, No. 1, pp. 169–177
Publisher
Springer Nature
Publication Date
July 2018
DOI
10.1007/s10549-018-4734-x
ISSN
0167-6806